The stock of Arcutis Biotherapeutics Inc (ARQT) has seen a -10.05% decrease in the past week, with a -7.78% drop in the past month, and a 175.68% flourish in the past quarter. The volatility ratio for the week is 10.87%, and the volatility levels for the past 30 days are at 9.08% for ARQT. The simple moving average for the past 20 days is -3.02% for ARQT’s stock, with a 57.26% simple moving average for the past 200 days.
Is It Worth Investing in Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Right Now?
Additionally, the 36-month beta value for ARQT is 1.11. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ARQT is 97.38M and currently, short sellers hold a 19.77% ratio of that float. The average trading volume of ARQT on April 15, 2024 was 4.67M shares.
ARQT) stock’s latest price update
Arcutis Biotherapeutics Inc (NASDAQ: ARQT)’s stock price has dropped by -14.14 in relation to previous closing price of 11.88. Nevertheless, the company has seen a loss of -10.05% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-28 that Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with Mizuho repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to Mizuho is $8 based on the research report published on January 03, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $4, previously predicting the price at $57. The rating they have provided for ARQT stocks is “Neutral” according to the report published on October 26th, 2023.
Goldman gave a rating of “Neutral” to ARQT, setting the target price at $6 in the report published on October 13th of the previous year.
ARQT Trading at 7.84% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.77% of loss for the given period.
Volatility was left at 9.08%, however, over the last 30 days, the volatility rate increased by 10.87%, as shares sank -6.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +73.76% upper at present.
During the last 5 trading sessions, ARQT fell by -10.05%, which changed the moving average for the period of 200-days by +20.43% in comparison to the 20-day moving average, which settled at $10.48. In addition, Arcutis Biotherapeutics Inc saw 215.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Heron Patrick J, who purchase 21,052 shares at the price of $9.50 back on Mar 04 ’24. After this action, Heron Patrick J now owns 8,785,284 shares of Arcutis Biotherapeutics Inc, valued at $199,994 using the latest closing price.
Watanabe Todd Franklin, the of Arcutis Biotherapeutics Inc, sale 14,903 shares at $11.12 during a trade that took place back on Mar 04 ’24, which means that Watanabe Todd Franklin is holding 874,533 shares at $165,739 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -4.04 for the present operating margin
- 0.91 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -4.39. The total capital return value is set at -0.82.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -1.22. The debt to equity ratio resting at 2.28. The interest coverage ratio of the stock is -8.11.
Currently, EBITDA for the company is -239.22 million with net debt to EBITDA at -0.5. When we switch over and look at the enterprise to sales, we see a ratio of 21.63. The receivables turnover for the company is 2.31for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.08.
Conclusion
In conclusion, Arcutis Biotherapeutics Inc (ARQT) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
